De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies

Abstract
Congenital heart disease (CHD) patients have an increased prevalence of extracardiac congenital anomalies (CAs) and risk of neurodevelopmental disabilities (NDDs). Exome sequencing of 1213 CHD parent-offspring trios identified an excess of protein-damaging de novo mutations, especially in genes highly expressed in the developing heart and brain. These mutations accounted for 20% of patients with CHD, NDD, and CA but only 2% of patients with isolated CHD. Mutations altered genes involved in morphogenesis, chromatin modification, and transcriptional regulation, including multiple mutations in RBFOX2, a regulator of mRNA splicing. Genes mutated in other cohorts examined for NDD were enriched in CHD cases, particularly those with coexisting NDD. These findings reveal shared genetic contributions to CHD, NDD, and CA and provide opportunities for improved prognostic assessment and early therapeutic intervention in CHD patients.
Funding Information
  • Howard Hughes Medical Institute
  • National Heart, Lung, and Blood Institute
  • Simons Foundation for Autism Research
  • Wellcome Trust
  • Harvard Medical School
  • Heart and Stroke Foundation of Ontario
  • British Heart Foundation
  • Arthritis Research UK
  • Academy of Medical Sciences
  • Imperial College London
  • Leducq Foundation
  • National Human Genome Research Institute of the National Institutes of Health (NIH)
  • National Research Science Award
  • NIHR Cardiovascular Biomedical Research Unit at Royal Brompton
  • Harefield NHS Foundation Trust
  • Ted Roger Centre for Heart Research
  • Kostin Family Innovation Fund
  • Aaron Stern Professorship at the University of Michigan
  • Braylon’s Gift of Hope Fund